



How the treatment works



When patients have Natural-Killer T-Cell Lymphoma, the PD-L1 gene on their tumour cells binds with the PD-1 gene on their T-cells, preventing the T-cells from attacking the tumour cells.



Patients with a mutation in their PD-L1 gene can be treated with pembrolizumab. It blocks the PD-1 gene and prevents the two from binding, so the T-cells can attack the tumour cells.